Bupropion sustained release for treatment of tobacco dependence

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


Tobacco use is a global pandemic. The most common pharmacological treatments of tobacco use and dependence include nicotine replacement therapy and nonnicotine medications. Bupropion sustained release (SR) is the only first-line nonnicotine medication recommended by the US Public Health Service Clinical Practice Guideline. Randomized controlled clinical trials have shown that bupropion SR doubles abstinence rates compared with placebo. Long-term treatment with bupropion SR may reduce or delay smoking relapse. Bupropion SR has an excellent adverse effect profile, although a risk exists for serious adverse effects such as seizures. The risk of serious adverse effects associated with bupropion SR can be reduced by careful selection of patients. This article reviews the evidence of efficacy and common adverse effects of bupropion SR and delineates the clinical characteristics of patients at higher risk for adverse effects when bupropion SR is prescribed for treatment of tobacco use and dependence.

Original languageEnglish (US)
Pages (from-to)1020-1024
Number of pages5
JournalMayo Clinic proceedings
Issue number8
StatePublished - Aug 1 2003

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Bupropion sustained release for treatment of tobacco dependence'. Together they form a unique fingerprint.

Cite this